Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer
Evolving HIV viral strains and the adverse side effects associated with long-term exposure to current treatments propel scientists to continue exploring alternative HIV treatments. In a new study, a University of Missouri researcher has identified broad-spectrum aptamers. Aptamers are synthetic molecules that prevent the HIV virus from reproducing. In lab tests, aptamers known as RT5,
Full Post: Researcher refines aptamers to prevent HIV resistance
Medarex, Inc. has announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer.
Studies suggest that the PD-1 signaling pathway may play an important role in tumor evasion and escape from host immune responses and may also promote the persistence of certain chronic viral infections.
The Phase 1b clinical trial is designed to primarily evaluate the safety and tolerability of repeated dosing of MDX-1106 in adult patients with solid tumors and will also provide a preliminary assessment of the anti-tumor activity of multiple doses of MDX-1106 (1, 3 or 10 mg/kg) in these patients. The tumors to be studied include malignant melanoma, renal cell cancer, castrate-resistant prostate cancer and non-small cell lung carcinoma. This open label study is expected to enroll up to 76 patients and will be conducted in multiple sites in the United States.
“We believe that anti-PD-1 antibodies could represent the next stage in immunotherapy with a promising mechanism of action and potential for marked synergy with anti-CTLA4 antibodies,” said Geoffrey M. Nichol, MBChB, Senior Vice President of Product Development at Medarex. “Preliminary results from our single-dose Phase 1 study demonstrated an acceptable safety profile and initial evidence of anti-tumor activity in cancer. We look forward to the further development of this novel immunotherapy in cancer and, in a separate clinical trial, hepatitis C.”
In May 2005, Ono entered into a collaboration agreement with Medarex to research and develop a fully human anti-PD-1 antibody for the treatment of cancer. The two companies plan to share the costs and responsibilities of research and product development up to the completion of a Phase 2 clinical study in each party’s territory. Thereafter, each company will be fully responsible for any continued development and any commercialization in its exclusive territory; Medarex’s exclusive territory is North America, and Ono’s exclusive territory is all areas outside of North America.
MDX-1106/ONO-4538 is a novel fully human antibody designed to target and inhibit the function of PD-1 (programmed cell death 1), a receptor expressed on the surface of activated lymphocytes (T-cells). The binding of PD-1 with one of two ligands (PD-L1 or PD-L2) is an important negative regulation pathway that suppresses or inhibits activated lymphocytes. Recent research has noted increased PD-1 expression levels on antigen specific T-cells in both the oncology and chronic infectious disease settings, as well as a strong correlation between increased PD-L1 expression on tumors and a negative survival prognosis in cancer patients. Preclinical studies indicate that antibodies targeting the PD-1 signaling pathway reinvigorate antigen-specific T-cell responses and promote an immune response to fight tumors and infectious diseases.
As previously presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO), interim Phase 1 data in patients with recurrent or treatment-refractory cancer indicated preliminary evidence of anti-tumor activity or tumor regression in patients with recurrent or treatment-refractory cancer, as well as a favorable safety, tolerability and pharmacokinetic profile of single-dose MDX-1106. Data from the completed Phase 1 study are expected to be presented at an upcoming medical meeting.
MDX-1106/ONO-4538 is being investigated in both the oncology and infectious disease settings. In addition to the Phase 1b study in cancer, a Phase 1 trial is ongoing for the treatment of hepatitis C. In September 2008, Ono filed an IND to allow the initiation of a single and multi-dose Phase 1 clinical study in patients with advanced solid malignancies in Japan. MDX-1106/ONO-4538 may also have the potential to be used synergistically in combination with other treatment modalities, including with anti-CTLA-4 blockade.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational. The contract, awarded by the National Institute
Full Post: Sequella, Inc. drug compound SQ109 selected for phase 1B clinical trial program
The Burzynski Research Institute, Inc. (BRI) has announced that its antineoplaston A10 and antineoplaston AS2-1 therapy (ANP) has been granted orphan drug designation by the U.S. Food and Drug Administration (”FDA”) for the treatment of gliomas. It is estimated that in 2008 more than 21,000 men and women in the U.S. will be diagnosed with
Full Post: Antineoplaston treatment for gliomas granted orphan drug designation by FDA
Peregrine Pharmaceuticals, Inc. has announced that updated preliminary data from the first stage of its Phase II trial evaluating bavituximab in combination with docetaxel showed that 10 of 14 (71%) evaluable breast cancer patients achieved an objective tumor response according to RECIST criteria. The company also reported that patient screening has begun in the
Full Post: Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in advanced breast cancer
Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, has announced that the Company has completed a single and multi-dose Phase I study of CMX001 in healthy volunteers. This study supports the further development of the drug for multiple dsDNA infections. The Company has initiated the first Phase II multi-dose clinical trial in patients.
Full Post: Chimerix completes phase I study and starts phase II multi-dose trial for CMX001
Bionovo, Inc. has announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology’s Fifth International Conference in Atlanta, Georgia. The Company’s oral presentation was selected as a top scoring abstract and will be presented as a
Full Post: Bionovo to present phase 1B trial results of BZL101 in metastatic breast cancer